Oryzon Initiates Multiple Ascending Dose Cohorts In ORY-2001 Phase 1 Clinical Trial

27 July 2016 BARCELONA, SPAIN and CAMBRIDGE, MA, Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the initiation of multiple ascending dose cohorts in the on-going Phase 1 study of its proprietary oral epigenetic drug ORY-2001 in healthy subjects. This Phase I study is being conducted in Spain. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗